131 related articles for article (PubMed ID: 2564451)
1. IMP dehydrogenase: inhibition by the anti-leukemic drug, tiazofurin.
Yamada Y; Natsumeda Y; Yamaji Y; Jayaram HN; Tricot GJ; Hoffman R; Weber G
Leuk Res; 1989; 13(2):179-84. PubMed ID: 2564451
[TBL] [Abstract][Full Text] [Related]
2. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase.
Yamada Y; Natsumeda Y; Weber G
Biochemistry; 1988 Mar; 27(6):2193-6. PubMed ID: 2897864
[TBL] [Abstract][Full Text] [Related]
3. IMP dehydrogenase and action of antimetabolites in human cultured blast cells.
Yamada Y; Goto H; Yoshino M; Ogasawara N
Biochim Biophys Acta; 1990 Mar; 1051(3):209-14. PubMed ID: 1968764
[TBL] [Abstract][Full Text] [Related]
4. Dehydrogenase binding by tiazofurin anabolites.
Goldstein BM; Bell JE; Marquez VE
J Med Chem; 1990 Apr; 33(4):1123-7. PubMed ID: 1969483
[TBL] [Abstract][Full Text] [Related]
5. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
[TBL] [Abstract][Full Text] [Related]
6. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
Weber G; Jayaram HN; Lapis E; Natsumeda Y; Yamada Y; Yamaji Y; Tricot GJ; Hoffman R
Adv Enzyme Regul; 1988; 27():405-33. PubMed ID: 2907968
[TBL] [Abstract][Full Text] [Related]
7. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
[TBL] [Abstract][Full Text] [Related]
8. Targets and markers of selective action of tiazofurin.
Weber G; Natsumeda Y; Pillwein K
Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
[TBL] [Abstract][Full Text] [Related]
9. Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
Look KY; Sutton GP; Natsumeda Y; Eble JN; Stehman FB; Ehrlich CE; Olah E; Prajda N; Bosze P; Eckhardt S
Gynecol Oncol; 1992 Oct; 47(1):66-70. PubMed ID: 1358769
[TBL] [Abstract][Full Text] [Related]
10. Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activity.
Cooney DA; Jayaram HN; Glazer RI; Kelley JA; Marquez VE; Gebeyehu G; Van Cott AC; Zwelling LA; Johns DG
Adv Enzyme Regul; 1983; 21():271-303. PubMed ID: 6152729
[TBL] [Abstract][Full Text] [Related]
11. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: implications on enzyme mechanism.
Hedstrom L; Wang CC
Biochemistry; 1990 Jan; 29(4):849-54. PubMed ID: 1971185
[TBL] [Abstract][Full Text] [Related]
13. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
Wright DG; Boosalis MS; Waraska K; Oshry LJ; Weintraub LR; Vosburgh E
Anticancer Res; 1996; 16(6A):3349-51. PubMed ID: 9042310
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin.
Weber G; Yamaji Y; Olah E; Natsumeda Y; Jayaram HN; Lapis E; Zhen WN; Prajda N; Hoffman R; Tricot GJ
Adv Enzyme Regul; 1989; 28():335-56. PubMed ID: 2576178
[TBL] [Abstract][Full Text] [Related]
15. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture.
Lee HJ; Pawlak K; Nguyen BT; Robins RK; Sadée W
Cancer Res; 1985 Nov; 45(11 Pt 1):5512-20. PubMed ID: 2865005
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of tiazofurin and its arabinose and xylose analogues in K562 cells.
Zhen W; Jayaram HN; Marquez VE; Goldstein BM; Cooney DA; Weber G
Biochem Biophys Res Commun; 1991 Oct; 180(2):933-8. PubMed ID: 1683233
[TBL] [Abstract][Full Text] [Related]
17. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
Sokoloski JA; Sartorelli AC
Mol Pharmacol; 1985 Dec; 28(6):567-73. PubMed ID: 2867464
[TBL] [Abstract][Full Text] [Related]
18. Tiazofurin: molecular and clinical action.
Weber G; Prajda N; Abonyi M; Look KY; Tricot G
Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
[TBL] [Abstract][Full Text] [Related]
19. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
20. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).
Ahluwalia GS; Cooney DA; Marquez VE; Jayaram HN; Johns DG
Biochem Pharmacol; 1986 Nov; 35(21):3783-90. PubMed ID: 2877671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]